Puma Biotechnology, Inc. $PBYI Shares Sold by Globeflex Capital L P

Globeflex Capital L P trimmed its position in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 22.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 349,651 shares of the biopharmaceutical company’s stock after selling 102,955 shares during the quarter. Globeflex Capital L P’s holdings in Puma Biotechnology were worth $2,234,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its stake in Puma Biotechnology by 7.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,436,106 shares of the biopharmaceutical company’s stock worth $9,175,000 after purchasing an additional 96,503 shares during the period. O Shaughnessy Asset Management LLC boosted its stake in shares of Puma Biotechnology by 35.3% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 1,120,329 shares of the biopharmaceutical company’s stock valued at $6,666,000 after purchasing an additional 292,108 shares during the period. Geode Capital Management LLC boosted its stake in shares of Puma Biotechnology by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 994,345 shares of the biopharmaceutical company’s stock valued at $5,917,000 after purchasing an additional 10,823 shares during the period. Russell Investments Group Ltd. grew its holdings in shares of Puma Biotechnology by 4,823,365.0% in the third quarter. Russell Investments Group Ltd. now owns 964,693 shares of the biopharmaceutical company’s stock valued at $5,123,000 after purchasing an additional 964,673 shares in the last quarter. Finally, State Street Corp grew its holdings in shares of Puma Biotechnology by 17.2% in the fourth quarter. State Street Corp now owns 877,077 shares of the biopharmaceutical company’s stock valued at $5,219,000 after purchasing an additional 128,419 shares in the last quarter. 61.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Puma Biotechnology news, CEO Alan H. Auerbach sold 44,058 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $8.26, for a total transaction of $363,919.08. Following the completion of the transaction, the chief executive officer owned 7,261,671 shares in the company, valued at $59,981,402.46. The trade was a 0.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jay M. Moyes sold 22,000 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $7.22, for a total transaction of $158,840.00. Following the completion of the sale, the director directly owned 58,322 shares in the company, valued at approximately $421,084.84. This represents a 27.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 132,028 shares of company stock valued at $1,006,711 over the last ninety days. 22.20% of the stock is currently owned by corporate insiders.

Puma Biotechnology Price Performance

Shares of NASDAQ PBYI opened at $7.87 on Thursday. The company has a market cap of $400.58 million, a price-to-earnings ratio of 16.40 and a beta of 1.20. The stock’s 50-day moving average is $7.58 and its two-hundred day moving average is $7.03. Puma Biotechnology, Inc. has a 1-year low of $3.03 and a 1-year high of $8.75.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.09. Puma Biotechnology had a return on equity of 20.30% and a net margin of 10.69%.The business had revenue of $44.81 million during the quarter, compared to analysts’ expectations of $42.00 million. Equities research analysts anticipate that Puma Biotechnology, Inc. will post 0.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Weiss Ratings downgraded shares of Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Wall Street Zen cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, Puma Biotechnology presently has an average rating of “Hold”.

Puma Biotechnology Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.